Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPACT: Tafolecimab in ACS Patients Undergoing PCI
NCT06096909Phase 4Recruiting
- Sponsor
- National Center for Cardiovascular Disease
- Start
- Nov 2023
- Primary completion
- Mar 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of tafolecimab in acute coronary syndrome (ACS), sponsored by National Center for Cardiovascular Disease. Started Nov 2023; status: recruiting.
02
Drugs
tafolecimab
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT06096909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06096909.